Skip to content

Innovative Medicine
healthcare areas

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. Innovative Medicine /
      2. Immunology /
      3. Rheumatology

      Rheumatology

      For more than two decades, Johnson & Johnson has been providing patients and physicians with important therapies to treat rheumatoid arthritis (RA) and other rheumatic diseases, beginning with the development of tumor necrosis factor (TNF)-alpha inhibitors and continuing with the establishment of the first interleukin (IL)-12/IL-23 treatment.

      We remain focused on complementing our existing portfolio of large-molecule biologics with novel treatments and oral therapeutics in development to provide new options to patients, through a combination of internal research and development, external collaborations, and industry consortia. We are also advancing research in autoantbody-driven rheumatic diseases, such as sIdiopathic inflammatory myopathies (IIM), Sjögren’s disease (SjD), and Systemic Lupus Erythematosus (SLE).

      Keeping patients at the center of everything we do, Johnson & Johnson is committed to tirelessly pushing the boundaries of science to deliver innovative and transformational approaches for heumatic diseases building on the ever-evolving understanding of the immune system.

      Disease areas

      Newsroom

      See all latest rheumatology news by visiting our newsroom.

      Featured resources

      New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

      TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24 Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis